Inflammatory bowel disease and pregnancy: An update

Expert Review of Clinical Immunology

Volumn 6, Issue 4, 2010, Pages 643-657

  Kwan, Lola Y ^a   Mahadevan, Uma ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adalimumab; certolizumab; Crohns disease; inflammatory bowel disease; infliximab; pregnancy; ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; BALSALAZIDE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FISH OIL; FOLIC ACID; HYDROCORTISONE; IMMUNOGLOBULIN; INFLIXIMAB; LEVOFLOXACIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NORFLOXACIN; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PREDNISONE; PSV 23; QUINOLONE DERIVATIVE; ROTAVIRUS VACCINE; SALAZOSULFAPYRIDINE; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABORTION; ADRENAL INSUFFICIENCY; ANTICIPATION; BIRTH DEFECT; BONE ATROPHY; BREAST FEEDING; CARDIOVASCULAR DISEASE; CHILD; CLEFT FACE; CLEFT PALATE; CONGENITAL MALFORMATION; CROHN DISEASE; DELIVERY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIARRHEA; DISEASE ACTIVITY; EMBRYOPATHY; ENDOSCOPY; ENTERITIS; FEMALE FERTILITY; FEMALE INFERTILITY; FETUS WASTAGE; GASTROENTEROLOGY; GROWTH RETARDATION; HEALTH CARE; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; ILEITIS; INHERITANCE; INTRAUTERINE GROWTH RETARDATION; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; LACTATION; LIMB; MATERNAL CARE; MENTAL DEFICIENCY; MICROGNATHIA; NEUROLOGIC DISEASE; NONHUMAN; OBSTETRICS; PEDIATRICIAN; PHYSICIAN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PUERPERIUM; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SPONTANEOUS ABORTION; SUPPLEMENTATION; TERATOGENICITY; UROGENITAL TRACT DISEASE;

BREAST FEEDING; FEMALE; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK ASSESSMENT;

EID: 77954398132     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.35     Document Type: Review

References (151)

1. Andres PG, Friedman LS. Epidemiology and the natural course of infammatory bowel disease. Gastroenterol. Clin. North Am. 28(2), 255-281, vii (1999). (Pubitemid 29306479)
2. Orholm M, Fonager K, Sorensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic infammatory bowel disease. Am. J. Gastroenterol. 94(11), 3236-3238 (1999).
3. Bennett RA, Rubin PH, Present DH. Frequency of infammatory bowel disease in offspring of couples both presenting with infammatory bowel disease. Gastroenterology 100(6), 1638-1643 (1991).
4. Polito JM, Childs B, Mellits ED et al Crohn's disease: infuence of age at diagnosis on site and clinical type of disease. Gastroenterology 111(3), 580-586 (1996). (Pubitemid 26293220)
5. Menken J, Trussell J, Larsen U. Age and infertility. Science 233(4771), 1389-1394 (1986). (Pubitemid 17169372)
6. Olsen KO, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 122(1), 15-19 (2002). (Pubitemid 34049189)
7. Hudson M, Flett G, Sinclair TS et al Fertility and pregnancy in infammatory bowel disease. Int. J. Gynaecol. Obstet. 58(2), 229-237 (1997). (Pubitemid 27281303)
8. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 55(11), 1575-1580 (2006). (Pubitemid 44629206)
9. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 25(1), 52-56 (1984). (Pubitemid 14125747)
10. Johnson P, Richard C, Ravid A et al Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon Rectum 47(7), 1119-1126 (2004). (Pubitemid 38857058)
11. Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with infammatory bowel disease. Infamm. Bowel Dis. 13(5), 591-599 (2007). (Pubitemid 46799644)
12. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Infamm. Bowel Dis. 14(12), 1736-1750 (2008).
13. Mountifeld R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in infammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Infamm. Bowel Dis. 15(5), 720-725 (2009).
14. Gorgun E, Remzi FH, Goldberg JM et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery 136(4), 795-803 (2004). (Pubitemid 39311305)
15. Lepisto A, Sarna S, Tiitinen A, Jarvinen HJ. Female fertility and childbirth after ileal pouch-anal anastomosis for ulcerative colitis. Br. J. Surg. 94(4), 478-482 (2007). (Pubitemid 46624728)
16. Cornish JA, Tan E, Teare J et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis. Colon Rectum 50(8), 1128-1138 (2007). (Pubitemid 47087474)
17. Arkuran C, McComb P. Crohn's disease and tubal infertility: the effect of adhesion formation. Clin. Exp. Obstet. Gynecol. 27(1), 12-13 (2000). (Pubitemid 30156601)
18. Oresland T, Palmblad S, Ellstrom M et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int. J. Colorectal Dis. 9(2), 77-81 (1994). (Pubitemid 24157626)
19. Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with infammatory bowel disease in Leicestershire. Int. J. Colorectal Dis. 12(4), 220-224 (1997). (Pubitemid 27344514)
20. Stein SL, Michelassi F. How can fecundity be preserved in patients undergoing pelvic surgery? Nat. Clin. Pract. Gastroenterol. Hepatol. 5(6), 308-309 (2008). (Pubitemid 351803601)
21. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA 273(24), 1933-1936 (1995). (Pubitemid 24188701)
22. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J. Immunol. 151(9), 4562-4573 (1993). (Pubitemid 23318510)
23. Winger EE, Reed JL, Ashoush S et al. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am. J. Reprod. Immunol. 61(2), 113-120 (2009).
24. Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am. J. Gastroenterol 93(12), 2426-2430 (1998). (Pubitemid 29018549)
25. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with infammatory bowel disease-a population-based cohort study. Am. J. Obstet. Gynecol. 177(4), 942-946 (1997). (Pubitemid 27516071)
26. Norgard B, Fonager K, Sorensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am. J. Gastroenterol. 95(11), 3165-3170 (2000).
27. Lin HC, Chiu CC, Chen SF et al Ulcerative colitis and pregnancy outcomes in an Asian population. Am. J. Gastroenterol. 105(2), 387-394 (2010).
28. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with infammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol 97(3), 641-648 (2002).
29. Norgard B, Puho E, Pedersen L, Czeizel AE, Sorensen HT. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am. J. Gastroenterol. 98(9), 2006-2010 (2003). (Pubitemid 37185797)
30. Mahadevan U, Sandborn WJ, Li DK et al Pregnancy outcomes in women with infammatory bowel disease: a large community-based study from Northern California. Gastroenterology 133(4), 1106-1112 (2007). (Pubitemid 47494456)
31. Dotan I, Alper A, Rachmilewitz D et al The effect of infammatory bowel disease during pregnancy on long-term helath and illness in children of IBD patients-a multicenter Israeli study. Gastroenterology 136(5, Suppl. 1), A-15 (2009).
32. Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology 47(36), 1595-1598 (2000).
33. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand. J. Gastroenterol. 18(6), 735-742 (1983). (Pubitemid 13005019)
34. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in infammatory bowel disease. J. Matern. Fetal Neonatal Med. 15(4), 237-241 (2004). (Pubitemid 38686012)
35. Fedorkow DM, Persaud D, Nimrod CA. Infammatory bowel disease: a controlled study of late pregnancy outcome. Am. J. Obstet. Gynecol. 160(4), 998-1001 (1989). (Pubitemid 19122592)
36. Moser MA, Okun NB, Mayes DC, Bailey RJ. Crohn's disease, pregnancy, and birth weight. Am. J. Gastroenterol. 95(4), 1021-1026 (2000).
37. Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn's disease. Scand. J. Gastroenterol. 19(6), 724-732. (1984). (Pubitemid 14027520)
38. Agret F, Cosnes J, Hassani Z et al. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol. Ther. 21(5), 509-513 (2005). (Pubitemid 40381500)
39. Ubina-Aznar E, De Sola-Earle C, Rivera-Irigoin R et al. Crohn's disease and pregnancy. A descriptive and retrospective study. Gastroenterol. Hepatol. 29(5), 277-280 (2006). (Pubitemid 43875739)
40. Castiglione F, Pignata S, Morace F et al. Effect of pregnancy on the clinical course of a cohort of women with infammatory bowel disease. Ital. J. Gastroenterol. 28(4), 199-204 (1996). (Pubitemid 26248518)
41. Riis L, Vind I, Politi P et al. Does pregnancy change the disease course? A study in a European cohort of patients with infammatory bowel disease. Am. J. Gastroenterol. 101(7), 1539-1545 (2006). (Pubitemid 43982551)
42. Nelson JL, Hughes KA, Smith AG et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N. Engl. J. Med. 329(7), 466-471 (1993).
43. Cholongitas E, Papatheodoridis GV, Zappoli P et al. Combined HLA-DR and-DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Liver Transpl. 13(4), 552-557 (2007). (Pubitemid 46605858)
44. Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with infammatory bowel disease. Am. J. Gastroenterol. 99(8), 1523-1526 (2004). (Pubitemid 39180101)
45. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with infammatory bowel disease. Am. J. Gastroenterol. 100(1), 102-105 (2005). (Pubitemid 41623276)
46. Salem ML. Estrogen, a double-edged sword: modulation of TH1-and TH2-mediated infammations by differential regulation of TH1/TH2 cytokine production. Curr. Drug Targets Infamm. Allergy 3(1), 97-104 (2004).
47. Ostensen M, Forger F, Nelson JL et al. Pregnancy in patients with rheumatic disease: anti-infammatory cytokines increase in pregnancy and decrease post partum. Ann. Rheum. Dis. 64(6), 839-844 (2005). (Pubitemid 40733905)
48. Draca S, Levic Z. The possible role of prolactin in the immunopathogenesis of multiple sclerosis. Med. Hypotheses 47(2), 89-92 (1996). (Pubitemid 26271086)
49. Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and infammatory arthritis. Arthritis Rheum. 43(5), 1010-1015 (2000). (Pubitemid 30368177)
50. Berczi I. The role of the growth and lactogenic hormone family in immune function. Neuroimmunomodulation 1(4), 201-216 (1994).
51. Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in infammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am. J. Gastroenterol. 104(10), 2517-2523 (2009).
52. Klement E, Reif S. Breastfeeding and risk of infammatory bowel disease. Am. J. Clin. Nutr. 82(2), 486 (2005).
53. Jantchou P, Turck D, Balde M, Gower-Rousseau C. Breastfeeding and risk of infammatory bowel disease: results of a pediatric, population-based, case-control study. Am. J. Clin. Nutr. 82(2), 485-486 (2005).
54. Kilpatrick CC, Monga M. Approach to the acute abdomen in pregnancy. Obstet. Gynecol. Clin. North Am. 34(3), 389-402 (2007). (Pubitemid 47503678)
55. Dozois EJ, Wolff BG, Tremaine WJ et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis. Colon Rectum 49(1), 64-73 (2005).
56. Haq AI, Sahai A, Hallwoth S, Rampton DS, Dorudi S. Synchronous colectomy and caesarean section for fulminant ulcerative colitis: case report and review of the literature. Int. J. Colorectal Dis. 21(5), 465-469 (2005).
57. Mahadevan U, Martin C, Sandler R et al. A multi-center national prospective study of pregnancy and neonatal outcomes in women with infammatory bowel disease exposed to immunomodulators and biologic therapy. Gastroenterology 136(5, Suppl. 1), A-88 (2009).
58. Cornish J, Tan E, Teare J et al. A meta-analysis on the infuence of infammatory bowel disease on pregnancy. Gut 56(6), 830-837 (2007). (Pubitemid 46854200)
59. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn's disease. Am. J. Gastroenterol. 90(11), 1918-1922 (1995).
60. Beniada A, Benoist G, Maurel J, Dreyfus M. Infammatory bowel disease and pregnancy: report of 76 cases and review of the literature. J. Gynecol. Obstet. Biol. Reprod. (Paris) 34(6), 581-588 (2005). (Pubitemid 41441671)
61. Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am. J. Gastroenterol. 94(11), 3274-3278 (1999).
62. Hahnloser D, Pemberton JH, Wolff BG et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for infammatory bowel disease: immediate and long-term consequences and outcomes. Dis. Colon Rectum 47(7), 1127-1135 (2004). (Pubitemid 38857059)
63. Zelinkova Z, Mensink PB, Dees J, Kuipers EJ, van der Woude CJ. Reproductive wish represents an important factor infuencing therapeutic strategy in infammatory bowel diseases. Scand. J. Gastroenterol. 45(1), 46-50 (2010).
64. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for infammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 105(4), 1057-1060 (1993). (Pubitemid 23281493)
65. Marteau P, Tennenbaum R, Elefant E, Lemann M, Cosnes J. Foetal outcome in women with infammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment. Pharmacol. Ther. 12(11), 1101-1108 (1998). (Pubitemid 28508723)
66. Trallori G, d'Albasio G, Bardazzi G et al. 5-aminosalicylic acid in pregnancy: clinical report. Ital. J. Gastroenterol. 26(2), 75-78 (1994). (Pubitemid 24140199)
67. Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 52(2), 243-247 (2003). (Pubitemid 36115066)
68. Diav-Citrin O, Park YH, Veerasuntharam G et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 114(1), 23-28 (1998). (Pubitemid 28020950)
69. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1(8634), 383 (1989).
70. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta. Paediatr. Scand. 76(1), 137-142 (1987). (Pubitemid 17020978)
71. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol. 172 (2 Pt 1), 525-529 (1995).
72. Caro-Paton T, Carvajal A, Martin de Diego I et al. Is metronidazole teratogenic? A meta-analysis. Br. J. Clin. Pharmacol. 44(2), 179-182 (1997).
73. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet. Gynecol. 82(3), 348-352 (1993). (Pubitemid 23251351)
74. Sorensen HT, Larsen H, Jensen ES et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J. Antimicrob. Chemother. 44(6), 854-856 (1999).
75. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63(5), 186-192 (2001). (Pubitemid 32417247)
76. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynaecol. 105(3), 322-327 (1998) (Pubitemid 28123583)
77. American Academy of Pediatrics. Committee on Drugs. Naloxone use in newborns. Pediatrics 65(3), 667-669 (1980).
78. Niebyl JR. Antibiotics and other anti-infective agents in pregnancy and lactation. Am. J. Perinatol. 20(8), 405-414 (2003).
79. Larsen H, Nielsen GL, Schonheyder HC, Olesen C, Sorensen HT. Birth outcome following maternal use of fuoroquinolones. Int. J. Antimicrob. Agents 18(3), 259-262 (2001). (Pubitemid 32979199)
80. Loebstein R, Addis A, Ho E et al. Pregnancy outcome following gestational exposure to fuoroquinolones: a multicenter prospective controlled study. Antimicrob. Agents Chemother. 42(6), 1336-1339 (1998). (Pubitemid 28257627)
81. Briggs G. Drugs in Pregnancy and Lactation. Briggs G, Yaffe Sumner FR (Eds). Lippincott Williams &Wilkins, PA, USA (2005).
82. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur. J. Obstet. Gynecol. Reprod. Biol. 97(2), 188-192 (2001). (Pubitemid 32645654)
83. Berkovitch M, Diav-Citrin O, Greenberg R et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br. J. Clin. Pharmacol. 58(3), 298-302 (2004). (Pubitemid 39209063)
84. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am. J. Med. Genet. 86(3), 242-244 (1999). (Pubitemid 29465870)
85. Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6), 385-392 (2000).
86. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after frst trimester exposure to corticosteroids: a prospective controlled study. Reprod. Toxicol. 18(1), 93-101 (2004). (Pubitemid 38175451)
87. Armenti VT, Moritz MJ, Cardonick EH, Davison JM. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs 62(16), 2361-2375 (2002). (Pubitemid 35316386)
88. Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. Neonatology 94(4), 306-309 (2008).
89. Beaulieu DB, Ananthakrishnan AN, Issa M et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Infamm. Bowel Dis. 15(1), 25-28 (2009).
90. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr. Med. Res. Opin. 21(7), 1075-1084 (2005).
91. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J. Allergy Clin. Immunol. 111(4), 736-742 (2003). (Pubitemid 36470242)
92. Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 60(1), 10-12 (1999). (Pubitemid 29338849)
93. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 108, 776-789 (2001).
94. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 65(5), 240-261 (2002).
95. de Boer NK, Jarbandhan SV, de Graaf P et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol. 101(6), 1390-1392 (2006). (Pubitemid 43830009)
96. Norgard B, Pedersen L, Fonager K, Rasmussen SN, Sorensen HT. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol. Ther. 17(6), 827-834 (2003). (Pubitemid 36418880)
97. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in infammatory bowel disease. Gastroenterology 99(2), 443-446 (1990). (Pubitemid 20219101)
98. Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with infammatory bowel disease: a retrospective cohort study. Gastroenterology 124(1), 9-17 (2003). (Pubitemid 36055333)
99. Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with infammatory bowel disease on azathioprine. A district general hospital experience. Digestion 62(4), 249-254 (2000).
100. Moskovitz DN, Bodian C, Chapman ML et al. The effect on the fetus of medications used to treat pregnant infammatory bowel-disease patients. Am. J. Gastroenterol. 99(4), 656-661 (2004). (Pubitemid 38607969)
101. Zlatanic J, Korelitz BI, Rajapakse R et al. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for infammatory bowel disease. J. Clin. Gastroenterol. 36(4), 303-309 (2003). (Pubitemid 36331610)
102. Coelho J, Beaugerie L, Colombel J-F et al. Pregnancy outcome in infammatory bowel disease for women treated with thiopurine: cohort from the CESAME study. Gastroenterology 136(5 Suppl. 1), A-27 (2009).
103. Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am. J. Gastroenterol. 102(7), 1406-1413 (2007). (Pubitemid 46976292)
104. Goldstein LH, Dolinsky G, Greenberg R et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res. A Clin. Mol. Teratol. 79(10), 696-701 (2007). (Pubitemid 47584193)
105. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res. A Clin. Mol. Teratol. 85(7), 647-654 (2009).
106. Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann. Pharmacother. 40(12), 2269-2272 (2006). (Pubitemid 44954453)
107. Gardiner SJ, Gearry RB, Roberts RL et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br. J. Clin. Pharmacol. 62(4), 453-456 (2006).
108. Sau A, Clarke S, Bass J et al. Azathioprine and breastfeeding: is it safe? BJOG 114(4), 498-501 (2007).
109. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol. Ther. 28(10), 1209-1213 (2008).
110. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71(8), 1051-1055 (2001). (Pubitemid 32448816)
111. Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V. Pregnancy outcome in liver transplant recipients. Obstet. Gynecol. 102(1), 121-128 (2003). (Pubitemid 36792133)
112. Angelberger S, Reinisch W, Dejaco C. Prevention of abortion by ciclosporin treatment of fulminant ulcerative colitis during pregnancy. Gut 55(9), 1364-1365 (2006). (Pubitemid 44277375)
113. Bertschinger P, Himmelmann A, Risti B, Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am. J. Gastroenterol. 90(2), 330 (1995).
114. Reindl W, Schmid RM, Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut 56(7), 1019 (2007). (Pubitemid 46999089)
115. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of infammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am. J. Gastroenterol. 103(5), 1203-1209 (2008). (Pubitemid 351677969)
116. Branche J, Cortot A, Bourreille A et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Infamm. Bowel Dis. 15(7), 1044-1048 (2009).
117. Jain A, Venkataramanan R, Fung JJ et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 64(4), 559-565 (1997). (Pubitemid 27377184)
118. Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl. Int. 13(Suppl. 1), S299-S300 (2000). (Pubitemid 32064826)
119. Jain AB, Reyes J, Marcos A et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 76(5), 827-832 (2003). (Pubitemid 37140228)
120. Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 54(12), 1822-1823 (2005). (Pubitemid 41697694)
121. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
122. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). (Pubitemid 41770166)
123. Simister NE. Placental transport of immunoglobulin G. Vaccine 21(24), 3365-3369 (2003).
124. Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infiximab to the newborn. Clin. Gastroenterol. Hepatol. 4(10), 1255-1258 (2006). (Pubitemid 44512222)
125. Mahadevan U, Terdiman J, Church J et al. Infiximab levels in infants born to women with infammatory bowel disease. Gastroenterology 132(4 Suppl. 2), A144 (2007).
126. Lichtenstein G, Cohen RD, Feagan BG et al. Safety of infiximab in Crohn's disease: data from the 5000-patient TREAT registry. Gastroenterology 126(4 Suppl.), A54 (2004).
127. Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infiximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. 99(12), 2385-2392 (2004). (Pubitemid 40039370)
128. Mahadevan U, Kane S, Sandborn WJ et al. Intentional infiximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol. Ther. 21(6), 733-738 (2005). (Pubitemid 40469001)
129. Schnitzler F, Fidder H, Ferrante M et al. Intentional treatmetn with infiximab during pregnancy in women with infammatory bowel disease. Gastroenterology 132(4 Suppl. 2), Abstract 958 (2007).
130. Kane S, Ford J, Cohen R, Wagner C. Absence of infiximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J. Clin. Gastroenterol. 43(7), 613-616 (2009).
131. Peltier M, James D, Ford J et al. Infiximab levels in breast-milk of a nursing Crohn's patient. Am. J. Gastroenterol. 96(9 Suppl. 1), P258 (2001).
132. Anolik JH, Ravikumar R, Barnard J et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180(2), 688-692 (2008).
133. Mahadevan U, Kane S, Church J, Vasiliauskas E, Sandborn W, Dubinsky M. The effect of maternal peripartum infiximab use on neonatal immune response. Gastroenterology 134(4 Suppl. 1), A69 (2008).
134. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of infuenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34(2), 272-279 (2007). (Pubitemid 46255742)
135. Melmed GY, Agarwal N, Frenck RW et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with infammatory bowel disease. Am. J. Gastroenterol. 105(1), 148-154 (2010).
136. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig. Dis. Sci. 51(11), 2045-2047 (2006).
137. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Infamm. Bowel Dis. 12(8), 827-828 (2006). (Pubitemid 44253768)
138. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 54(6), 890 (2005).
139. Lichtenstein GR, Thomsen OO, Schreiber S et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to months. Clin. Gastroenterol. Hepatol. DOI:10.1016/j.cgh.2010.01.014 (2010) (Epub ahead of print).
140. Nesbitt A, Brown D, Stephens S, Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus pegylated Fab'. Am. J. Gastroenterol. 101(S2), Abstract 119 (2006).
141. Mahadevan U, Siegel C, Abreu M. Certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology 136(5), 960 (2009).
142. Rossi E, Costa M. Fish oil derivatives as a prophylaxis of recurrent miscarriage associated with antiphospholipid antibodies (APL): a pilot study. Lupus 2(5), 319-323 (1993). (Pubitemid 24003455)
143. Olsen SF, Sorensen JD, Secher NJ et al. Randomised controlled trial of effect of fsh-oil supplementation on pregnancy duration. Lancet 339(8800), 1003-1007 (1992).
144. Patlas N, Golomb G, Yaffe P et al. Transplacental effects of bisphosphonates on fetal skeletal ossifcation and mineralization in rats. Teratology 60(2), 68-73 (1999). (Pubitemid 29397194)
145. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod. Toxicol. 22(4), 578-579 (2006). (Pubitemid 44548327)
146. Levy S, Fayez I, Taguchi N et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44(3), 428-430 (2009).
147. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet. Gynecol. 114(6), 1326-1331 (2009).
148. Qureshi WA, Rajan E, Adler DG et al. ASGE guideline: guidelines for endoscopy in pregnant and lactating women. Gastrointest. Endosc. 61(3), 357-362 (2005). (Pubitemid 40349025)
149. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infiximab maintenance: a randomized trial. Gastroenterology 134(7), 1861-1868 (2008). (Pubitemid 351790744)
150. Administration FDA. Regulations. 44, 37434-37467 (1980).
151. Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology 131(1), 278-282 (2006). (Pubitemid 44015758)